SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 15, 2018--
Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company
discovering and developing innovative immuno-oncology protein
therapeutics, today announced the appointment of Bryan Irving, Ph.D., as
Executive Vice President and Chief Scientific Officer.
“We are delighted to promote Bryan to this important leadership role.
Bryan will set forth the discovery strategy and priorities for the
optimal use of our comprehensive IND engine to expand our product
pipeline,” said Aron Knickerbocker, chief executive officer of Five
Prime Therapeutics. “In addition to his leadership and managerial
abilities, Bryan brings a passion for innovative science and extensive
immuno-oncology experience. Among his most notable contributions is his
inventorship and leadership in developing atezolizumab (Tecentriq®),
which is now approved for the treatment of several cancers. We look
forward to his future contributions in helping us identify new targets,
which could translate into new drug candidates that help patients in
ways never before possible."
Dr. Irving joined Five Prime in August 2017 as the Vice President of
Research. Prior to joining Five Prime, Dr. Irving was at CytomX
Therapeutics, where he most recently served as Vice President of Cancer
Immunology, leading efforts to generate protease-activatable
immunotherapies designed to mobilize anti-tumor immunity locally in the
tumor microenvironment. His research has focused primarily on exploring
ways to modulate T cell activity for therapeutic benefit in both
autoimmune and oncology settings. Dr. Irving's doctoral work, performed
in the laboratory of Dr. Art Weiss at University of California, San
Francisco (UCSF), pioneered the single-chain chimeric antigen receptor
(CAR) technology now being used in patients’ T cells to treat
hematologic malignancies. Following post-doctoral work at Harvard and
UCSF on early T cell development, Dr. Irving joined Genentech in 2001
where he worked for 12 years in a joint appointment with the Departments
of Immunology and Oncology/Cancer Immunotherapy. Dr. Irving left
Genentech in 2013 to join CytomX Therapeutics.
Dr. Irving received a Ph.D. in Immunology from the University of
California, San Francisco and a B.A. in Physiology from the University
of California, Berkeley. In addition, Dr. Irving studied clarinet at the
Eastman School of Music at the University of Rochester.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative
therapeutics to improve the lives of patients with serious diseases.
Five Prime's comprehensive discovery platform, which encompasses
virtually every medically relevant extracellular protein, positions it
to explore pathways in cancer, inflammation and their intersection in
immuno-oncology, an area with significant therapeutic potential and the
focus of the company's R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical companies
and has promising product candidates in clinical and late preclinical
development. For more information, please visit www.fiveprime.com
or follow us on LinkedIn,
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking statements
are based on Five Prime's expectations and assumptions as of the date of
this press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results to
differ from those expressed or implied in the forward-looking statements
in this press release are discussed in Five Prime's filings with the
U.S. Securities and Exchange Commission, including the "Risk Factors"
contained therein. Except as required by law, Five Prime assumes no
obligation to update any forward-looking statements contained herein to
reflect any change in expectations, even as new information becomes
View source version on businesswire.com: https://www.businesswire.com/news/home/20180515006547/en/
Source: Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc.
Heather Rowe, 415-365-5737
Director, Investor Relations and Corporate Communications